Jpmorgan Chase & CO Adaptimmune Therapeutics PLC Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 882,331 shares of ADAP stock, worth $247,052. This represents 0.0% of its overall portfolio holdings.

Number of Shares
882,331
Previous 916,941 3.77%
Holding current value
$247,052
Previous $495,000 64.44%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$0.2 - $0.65 $6,922 - $22,496
-34,610 Reduced 3.77%
882,331 $176,000
Q4 2024

Feb 12, 2025
SELL
$0.54 - $0.95 $69,439 - $122,162
-128,592 Reduced 12.3%
916,941 $495,000
Q3 2024

Dec 26, 2024
BUY
$0.92 - $1.39 $7,631 - $11,530
8,295 Added 0.8%
1,045,533 $993,000
Q3 2024

Nov 08, 2024
BUY
$0.92 - $1.39 $7,631 - $11,530
8,295 Added 0.8%
1,045,533 $993,000
Q2 2024

Dec 26, 2024
SELL
$0.83 - $1.47 $6,884 - $12,193
-8,295 Reduced 0.79%
1,037,238 $1.02 Million
Q2 2024

Aug 12, 2024
BUY
$0.83 - $1.47 $101,432 - $179,645
122,208 Added 13.36%
1,037,238 $1.02 Million
Q1 2024

Dec 26, 2024
SELL
$0.7 - $1.75 $91,352 - $228,380
-130,503 Reduced 12.48%
915,030 $1.45 Million
Q1 2024

May 10, 2024
SELL
$0.7 - $1.75 $9,235 - $23,089
-13,194 Reduced 1.42%
915,030 $1.45 Million
Q4 2023

Dec 26, 2024
SELL
$0.43 - $0.79 $50,442 - $92,674
-117,309 Reduced 11.22%
928,224 $733,000
Q4 2023

Feb 12, 2024
SELL
$0.43 - $0.79 $44,372 - $81,522
-103,193 Reduced 10.0%
928,224 $733,000
Q3 2023

Nov 14, 2023
SELL
$0.73 - $1.04 $199,652 - $284,436
-273,497 Reduced 20.96%
1,031,417 $804,000
Q2 2023

Aug 11, 2023
BUY
$0.9 - $1.51 $963 - $1,617
1,071 Added 0.08%
1,304,914 $1.2 Million
Q1 2023

May 11, 2023
BUY
$1.06 - $2.16 $320,894 - $653,898
302,731 Added 30.24%
1,303,843 $1.42 Million
Q4 2022

Feb 13, 2023
SELL
$1.05 - $2.53 $6,006 - $14,471
-5,720 Reduced 0.57%
1,001,112 $1.46 Million
Q3 2022

Nov 14, 2022
SELL
$1.06 - $2.41 $495,370 - $1.13 Million
-467,331 Reduced 31.7%
1,006,832 $1.08 Million
Q2 2022

Aug 11, 2022
BUY
$1.33 - $2.28 $98,949 - $169,627
74,398 Added 5.32%
1,474,163 $2.51 Million
Q1 2022

May 11, 2022
SELL
$1.73 - $4.06 $135,412 - $317,788
-78,273 Reduced 5.3%
1,399,765 $2.88 Million
Q4 2021

Feb 10, 2022
SELL
$3.5 - $5.68 $413,780 - $671,506
-118,223 Reduced 7.41%
1,478,038 $5.54 Million
Q3 2021

Nov 12, 2021
BUY
$3.44 - $6.37 $5.49 Million - $10.2 Million
1,596,261 New
1,596,261 $8.25 Million

Others Institutions Holding ADAP

# of Institutions
73
Shares Held
114M
Call Options Held
77.5K
Put Options Held
14.2K
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $45.7M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email